Latest

2 stories

Hide weekly roundups

Tuesday, September 8

Clinical readoutdaraxonrasib Revolution Medicines, Inc.sabizabulin

Veru advances oral sabizabulin toward Phase 2 in daraxonrasib-resistant pancreatic cancer

New preclinical data show sabizabulin overcomes resistance to Revolution Medicines' daraxonrasib, prompting Veru to drop a cardiovascular indication and pursue an FDA preIND meeting in Q4 2026.

SEC filing

Monday, August 10

Quarterly updateenobosarm Veru Inc.

Veru's Phase 2b PLATEAU trial fully enrolled with 239 obesity patients

Veru said the enobosarm-semaglutide combination trial exceeded its enrollment target as the company reported fiscal Q3 2026 results and a pending key patent allowance.

SEC filing